STI Stock Trade Intelligence
COV

CLEO DIAGNOSTICS LTD

Health Care · ASX:COV
$0.2700
0.00%
Market cap
$38M
Turnover
$930
Last price
$0.2700
Day change
0.00%
Announcements
16
Range, past year
Open 0.540 · Low 0.260 · Now 0.270 · High 0.900
Open COV in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

COV momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-11-16.
Momentum quality
24/100
Wyckoff phase
Downtrend2d
Trend stage
Breakdown
1 Day
+0.0%
1 Week
-6.9%
1 Month
-12.9%
1 Year
-50.0%
RSI
39
Avg daily range
6.1%

CLEO DIAGNOSTICS LTD scores 24 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.

On the Wyckoff cycle it sits in Downtrend, where it has been for 2 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.

Against the wider market it is currently underperforming and the institutional accumulation signal reads low.

Points to watch
  • 60d drawdown -32.5%
  • High volatility (ATR 6.1%)
  • Thin liquidity
  • Risk rating: Very High
  • Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

COV announcements

Recent price-sensitive releases.
  • 2026-11-12 CLEO Advances Toward Clinical Validation Progress Report
  • 2026-10-30 Quarterly activities and cashflow report Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
  • 2026-10-21 CLEO Screening Test Meets Rigorous Performance Targets Progress Report
  • 2026-10-13 CLEO Commences Analytical Validation Ahead of FDA Submission Progress Report
  • 2026-09-30 Cleo Files Patents for its Ovarian Cancer Screening Test Progress Report
  • 2026-09-24 CLEO Commences Ovarian Cancer Screening Test Development Progress Report
  • 2026-09-10 CLIA Certified Lab selected - Pivotal US Clinical Validation Progress Report
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.